Latest revenue
$37.2M
as of 2026-03-31
Latest net income
$-8.3M
as of 2026-03-31
Net margin
-22.3%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $378.9M
- Enterprise value
- $378.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $2.73
- 52-wk low
- $0.85
- Beta
- —
- Shares out
- 310.6M
5-year trend
What this company does
Pacific Biosciences builds DNA sequencing machines, chips, and reagents that read genomes with long, highly accurate 'HiFi' reads, used by researchers studying rare diseases, cancer, pathogens, crops, and livestock. The company earns revenue selling instruments and recurring consumables (SMRT Cells and reagents) plus related services to academic labs, hospitals, pharma, and agricultural customers. In January 2026 PacBio sold its short-read sequencing assets, including the 2023 Apton acquisition technology, to Illumina for roughly $48 million net, refocusing the business entirely on long-read HiFi sequencing.
Generated from PACB's filing dated 2026-02-25
Key risks
- Concentration risk: customer base skews to academic/government labs vulnerable to NIH and federal research funding cuts impacting capital equipment budgets.
- Strategic retreat: sold short-read sequencing assets (Apton tech) to rival Illumina for just $48.1M net, narrowing platform to long-read only.
- Competitive pressure: faces Illumina and Oxford Nanopore in long-read sequencing while ceding short-read market entirely back to Illumina.
Generated from PACB's filing dated 2026-02-25
Profitability
Gross margin
28.6%
18.2%Operating margin
-346.2%
12.4%Net margin
-341.5%
69.7%Return on equity
-10214.5%
16600.4%Return on assets
-69.7%
183.5%Leverage
Debt / equity
145.58×
9683.4%Long-term debt / equity
120.65×
9339.9%Debt / assets
99.3%
66.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $37.2M | +0.1% | $-8.3M | +98.1% | -22.3% |
Q4 2025 2025-12-31 | $44.6M | +13.8% | $-40.4M | -1802.7% | -90.4% |
Q3 2025 2025-09-30 | $38.4M | -3.8% | $-38.0M | +37.4% | -98.9% |
Q2 2025 2025-06-30 | $39.8M | +10.4% | $-41.9M | +75.8% | -105.4% |
Q1 2025 2025-03-31 | $37.2M | -4.3% | $-426.1M | -445.0% | -1146.8% |
Q4 2024 2024-12-31 | $39.2M | — | $2.4M | — | 6.0% |
Q3 2024 2024-09-30 | $40.0M | -28.2% | $-60.7M | +9.2% | -151.9% |
Q2 2024 2024-06-30 | $36.0M | -24.3% | $-173.3M | -148.2% | -481.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Laboratory Analytical Instruments · SIC 3826
Your notes
Keep private notes on PACB — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.3M
Net activity
−$1.3M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns PACB
Institutional value
$148.8M
Total shares held
113.4M
Distinct holders
132
-83 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 36.3M | $47.9M | -990.9K (-2.7%) | Trimmed |
| 2 | BlackRock, Inc. | 25.3M | $33.4M | +1.9M (+8.2%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 12.8M | $16.9M | — | New |
| 4 | Sumitomo Mitsui Trust Group, Inc. | 7.0M | $9.3M | -770.6K (-9.9%) | Trimmed |
| 5 | Nikko Asset Management Americas, Inc. | 7.0M | $9.2M | -770.6K (-9.9%) | Trimmed |
| 6 | Nuveen, LLC | 3.0M | $3.9M | +2.1M (+247.9%) | Added |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.9M | $3.8M | — | New |
| 8 | VANGUARD FIDUCIARY TRUST CO | 2.0M | $2.6M | — | New |
| 9 | IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 1.8M | $2.4M | -106.5K (-5.6%) | Trimmed |
| 10 | UBS Group AG | 1.6M | $2.2M | -1.5M (-48.3%) | Trimmed |
| 11 | Invesco Ltd. | 1.5M | $1.9M | +35.1K (+2.5%) | Added |
| 12 | JANE STREET GROUP, LLC | 1.4M | $1.8M | -110.4K (-7.4%) | Trimmed |
| 13 | BOURNE LENT ASSET MANAGEMENT INC | 951.1K | $1.3M | -16.0K (-1.7%) | Trimmed |
| 14 | DIMENSIONAL FUND ADVISORS LP | 899.5K | $1.2M | +575.8K (+177.9%) | Added |
| 15 | Bank of New York Mellon Corp | 813.4K | $1.1M | -21.2K (-2.5%) | Trimmed |
| 16 | Universal- Beteiligungs- und Servicegesellschaft mbH | 808.7K | $1.1M | +0 (+0.0%) | No change |
| 17 | Mirador Capital Partners LP | 604.9K | $798.4K | +13.9K (+2.3%) | Added |
| 18 | Russell Investments Group, Ltd. | 469.9K | $620.2K | +446.0K (+1866.0%) | Added |
| 19 | GROUP ONE TRADING LLC | 365.0K | $481.8K | -95.2K (-20.7%) | Trimmed |
| 20 | RHUMBLINE ADVISERS | 348.9K | $460.6K | -12.0K (-3.3%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
The $50M Illumina asset sale nets only $48.1M after Apton—does this signal Onso short-read is dead and write-downs are coming?
- 2
With Illumina now licensing your short-read IP, what non-compete or field-of-use restrictions limit PacBio's clinical market expansion?
- 3
Given persistent cash burn, what's your runway post-$48M proceeds, and when do you commit to a specific path to cash-flow breakeven?
Refreshed when PACB files a new report · last from 2026-02-25